Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN) and MannKind (MNKD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medline, Inc. Class A (MDLN – Research Report) and MannKind (MNKD – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medline, Inc. Class A (MDLN)
In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on Medline, Inc. Class A, with a price target of $55.00. The company’s shares closed last Wednesday at $49.31, close to its 52-week high of $50.28.
According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medline, Inc. Class A with a $47.74 average price target, implying a 0.8% upside from current levels. In a report issued on February 18, Piper Sandler also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
MannKind (MNKD)
In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on MannKind. The company’s shares closed last Wednesday at $3.65.
According to TipRanks.com, Ruiz is a 1-star analyst with an average return of
MannKind has an analyst consensus of Strong Buy, with a price target consensus of $9.67, a 74.5% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.
